Total Payments
$18,578
2024 Payments
$4,845
Companies
84
Transactions
859
Medicare Patients
602
Medicare Billing
$97,589
Payment Breakdown by Category
Food & Beverage$17,413 (93.7%)
Other$732.12 (3.9%)
Education$432.99 (2.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $17,413 | 844 | 93.7% |
| Long term medical supply or device loan | $732.12 | 8 | 3.9% |
| Education | $432.99 | 7 | 2.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,152 | 83 | $0 (2024) |
| Janssen Biotech, Inc. | $1,656 | 66 | $0 (2024) |
| Merck Sharp & Dohme LLC | $1,094 | 46 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $1,002 | 72 | $0 (2024) |
| Celgene Corporation | $736.76 | 40 | $0 (2024) |
| GENZYME CORPORATION | $735.18 | 38 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $618.60 | 30 | $0 (2024) |
| Incyte Corporation | $540.84 | 25 | $0 (2024) |
| Astellas Pharma US Inc | $536.22 | 19 | $0 (2024) |
| PFIZER INC. | $493.70 | 25 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $4,845 | 230 | Janssen Biotech, Inc. ($416.29) |
| 2023 | $3,771 | 172 | Novartis Pharmaceuticals Corporation ($439.13) |
| 2022 | $4,444 | 201 | Novartis Pharmaceuticals Corporation ($892.85) |
| 2021 | $3,252 | 149 | Novartis Pharmaceuticals Corporation ($510.66) |
| 2020 | $2,250 | 106 | Merck Sharp & Dohme Corporation ($256.98) |
| 2018 | $15.51 | 1 | AbbVie, Inc. ($15.51) |
All Payment Transactions
859 individual payment records from CMS Open Payments — Page 1 of 35
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/30/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $22.00 | General |
| Category: Oncology | ||||||
| 12/23/2024 | Coherus Biosciences Inc. | LOQTORZI (Biological) | Food and Beverage | In-kind items and services | $21.35 | General |
| Category: Oncology | ||||||
| 12/19/2024 | Sumitomo Pharma America, Inc. | ORGOVYX (Drug) | Food and Beverage | In-kind items and services | $15.29 | General |
| Category: HORMONE THERAPY | ||||||
| 12/17/2024 | PFIZER INC. | BOSULIF (Drug), ELREXFIO, ADCETRIS | Food and Beverage | In-kind items and services | $28.96 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 12/17/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $13.43 | General |
| 12/13/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | GILOTRIF (Drug) | Food and Beverage | In-kind items and services | $21.20 | General |
| Category: ONCOLOGY | ||||||
| 12/13/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Food and Beverage | In-kind items and services | $18.97 | General |
| Category: Oncology | ||||||
| 12/12/2024 | SOBI, INC | SYNAGIS (Drug) | Food and Beverage | In-kind items and services | $19.97 | General |
| Category: IMMUNOLOGY | ||||||
| 12/12/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $18.32 | General |
| Category: Oncology | ||||||
| 12/11/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $34.66 | General |
| Category: ONCOLOGY | ||||||
| 12/10/2024 | Karyopharm Therapeutics Inc. | XPOVIO (Drug) | Food and Beverage | In-kind items and services | $26.57 | General |
| Category: Oncology | ||||||
| 12/06/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $21.36 | General |
| Category: Oncology | ||||||
| 12/06/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $0.93 | General |
| Category: Oncology | ||||||
| 12/05/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Food and Beverage | In-kind items and services | $28.88 | General |
| Category: Oncology | ||||||
| 12/04/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $29.97 | General |
| Category: ONCOLOGY | ||||||
| 12/03/2024 | Tempus AI, Inc | — | Food and Beverage | In-kind items and services | $19.73 | General |
| 12/02/2024 | ABBVIE INC. | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $21.45 | General |
| Category: ONCOLOGY | ||||||
| 12/02/2024 | E.R. Squibb & Sons, L.L.C. | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $12.41 | General |
| Category: Hematology | ||||||
| 11/27/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $16.14 | General |
| Category: ONCOLOGY | ||||||
| 11/25/2024 | SOBI, INC | SYNAGIS (Drug) | Food and Beverage | In-kind items and services | $21.21 | General |
| Category: IMMUNOLOGY | ||||||
| 11/22/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Food and Beverage | In-kind items and services | $23.15 | General |
| Category: Oncology | ||||||
| 11/21/2024 | PFIZER INC. | ADCETRIS (Biological) | Food and Beverage | In-kind items and services | $19.97 | General |
| Category: Oncology | ||||||
| 11/20/2024 | Janssen Biotech, Inc. | TECVAYLI (Biological), TALVEY, DARZALEX | Food and Beverage | In-kind items and services | $32.32 | General |
| Category: Oncology | ||||||
| 11/20/2024 | Sumitomo Pharma America, Inc. | ORGOVYX (Drug) | Food and Beverage | In-kind items and services | $14.60 | General |
| Category: HORMONE THERAPY | ||||||
| 11/19/2024 | SOBI, INC | DOPTELET (Drug) | Food and Beverage | In-kind items and services | $24.78 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 193 | 396 | $98,280 | $38,498 |
| 2022 | 4 | 128 | 228 | $58,960 | $23,712 |
| 2021 | 4 | 103 | 197 | $51,430 | $21,692 |
| 2020 | 7 | 178 | 226 | $51,842 | $13,687 |
Total Patients
602
Total Services
1,047
Medicare Billing
$97,589
Procedure Codes
20
All Medicare Procedures & Services
20 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 70 | 214 | $53,500 | $20,497 | 38.3% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 48 | 86 | $19,350 | $8,296 | 42.9% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 36 | 36 | $11,880 | $5,061 | 42.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 26 | 26 | $8,450 | $2,800 | 33.1% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 13 | 34 | $5,100 | $1,845 | 36.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 42 | 96 | $24,000 | $9,523 | 39.7% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 35 | 81 | $18,225 | $6,765 | 37.1% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 32 | 32 | $10,560 | $5,179 | 49.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 19 | 19 | $6,175 | $2,245 | 36.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 36 | 115 | $28,750 | $12,155 | 42.3% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 26 | 26 | $8,580 | $4,211 | 49.1% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 26 | 41 | $9,225 | $3,494 | 37.9% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 15 | 15 | $4,875 | $1,832 | 37.6% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 18 | 31 | $8,010 | $3,535 | 44.1% |
| G9678 | Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | Office | 2020 | 22 | 22 | $8,800 | $3,450 | 39.2% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 60 | 65 | $18,330 | $3,296 | 18.0% |
| 96413 | Infusion of chemotherapy into a vein up to 1 hour | Office | 2020 | 14 | 21 | $7,689 | $1,720 | 22.4% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 14 | 14 | $5,882 | $851.91 | 14.5% |
| 96367 | Infusion into a vein for therapy prevention or diagnosis additional sequential infusion up to 1 hour | Office | 2020 | 12 | 29 | $2,735 | $707.93 | 25.9% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2020 | 38 | 44 | $396.00 | $126.42 | 31.9% |
About Laxmi Iyer, M.D.,
Laxmi Iyer, M.D., is a Medical Oncology healthcare provider based in Riverside, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/18/2010. The National Provider Identifier (NPI) number assigned to this provider is 1508185406.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Laxmi Iyer, M.D., has received a total of $18,578 in payments from pharmaceutical and medical device companies, with $4,845 received in 2024. These payments were reported across 859 transactions from 84 companies. The most common payment nature is "Food and Beverage" ($17,413).
As a Medicare-enrolled provider, Iyer has provided services to 602 Medicare beneficiaries, totaling 1,047 services with total Medicare billing of $97,589. Data is available for 4 years (2020–2023), covering 20 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Other Specialties Hematology & Oncology
- Location Riverside, CA
- Active Since 05/18/2010
- Last Updated 06/11/2020
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1508185406
Products in Payments
- KEYTRUDA (Biological) $1,072
- KISQALI (Drug) $856.03
- OPDIVO (Biological) $720.34
- IMBRUVICA (Drug) $674.00
- DARZALEX (Biological) $668.51
- Pomalyst (Drug) $540.81
- Lenvima (Drug) $492.05
- BRUKINSA (Drug) $424.84
- XPOVIO (Drug) $333.23
- SARCLISA (Biological) $331.36
- FOTIVDA (Drug) $293.90
- JAKAFI (Drug) $292.71
- LIBTAYO (Biological) $292.61
- MONJUVI (Drug) $290.56
- JEVTANA (Drug) $288.14
- TABRECTA (Drug) $258.24
- MEKINIST (Drug) $249.03
- ULTOMIRIS (Biological) $222.43
- ERLEADA (Drug) $222.08
- Enhertu (Drug) $211.19
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.